In contrast, in another study of 84 patients with UCTD in which 22 developed SLE after at least five years of follow-up, only anticardiolipin antibodies were found to predict development of SLE and another six patients developed other forms of connective tissue disease10. thought not to have SLE; and 161 (61%) were still considered to have potential SLE. In multivariable regression models, oral ulcers (OR 2.40, 95%CI 1.03-5.58), anti-dsDNA (OR 2.59, 95% CI 1.25-5.35) and baseline proteinuria or cellular casts (OR 16.20, 95%CI 1.63-161.02) Fanapanel hydrate were independent predictors of developing SLE. The most common other final diagnoses included fibromyalgia, Sj?gren’s syndrome, mixed connective tissue disease and cutaneous lupus. Conclusion Among patients with potential SLE at initial consultation, 21% were diagnosed with definite SLE within 6.3 years. Oral ulcers, anti-dsDNA and proteinuria or cellular casts were independent predictors of developing definite SLE. A better means of accurately identifying those who will develop SLE among those presenting with potential disease is necessary. strong class=”kwd-title” Keywords: systemic lupus erythematosus, prognosis, serology, presentation, manifestation, risk factor, diagnosis, incomplete lupus Introduction Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease with a diverse constellation of clinical features. As SLE can potentially lead to serious multi-system organ damage, early detection could have important implications for morbidity and management. However, due to the diverse manifestations of SLE and their evolution over time, it can be challenging to diagnose. Clinicians often use terms such as possible lupus, incomplete lupus, latent lupus, and undifferentiated connective tissue disease to describe patients who have features of SLE, but do not fulfill ACR classification criteria. Understanding which patient presentations Fanapanel hydrate are associated with the highest risk of developing into SLE would help in the development of studies regarding early treatment interventions, as well as provide both clinicians and patients with better risk assessment tools and inform clinical practice. Our aim was to identify factors associated with the evolution to SLE in a large cohort of patients thought by SLE-specialist rheumatologists to have potential SLE at initial consultation. Patients and Methods Study population All patients seen in the Brigham and Women’s Hospital (BWH) Lupus Center in Boston, Massachusetts for potential SLE since 1992 have been prospectively enrolled into the BWH Lupus Registry. Basic demographics, all American College of Rheumatology (ACR) criteria for the classification of SLE1, 2, all other presenting features of SLE, date of onset of first symptoms, date of SLE diagnosis, treating rheumatologist’s name, and whether the diagnosis was thought to be definite SLE, potential SLE, or not SLE per the treating rheumatologist, have been collected in the Lupus Registry. From these data, we identified patients seen at the BWH FRPHE Lupus Center who: (1) had an initial consultation between January 1, 1992 and Fanapanel hydrate December 31, 2012, (2) were thought to have potential SLE (but not definite) by their evaluating board certified rheumatologist, (3) had 1-3 ACR criteria for SLE classification at the initial consultation, and (4) had 2 further visits each 3 months apart to our Lupus Center. The Partners Healthcare Institutional Review Board (IRB) approved of all aspects of this study. Data Collection Patient data were retrieved from all electronic medical records from the first consultation through the last visit, on or before May 15, 2013. Clinical Fanapanel hydrate data collected from the initial consultation and all subsequent visits until study end included: the presence or absence of all Fanapanel hydrate ACR criteria for SLE1, 2, Raynaud’s phenomenon, alopecia, weight loss, fever, headache, fatigue, vasculitis, thromboses, sicca symptoms, cutaneous and neurologic manifestations. We also compiled laboratory data, including presence or absence of antinuclear antibodies (ANA), anti-double stranded DNA (ds-DNA), anti-Ro (SSA),anti-La (SSB), anti-Sm, anticardiolipin antibodies (aCL), anti-2 glycoprotein-1 antibodies, lupus anticoagulant, rheumatoid factor (RF), C3, C4 and CH50 complements, complete blood counts, and Coomb’s tests. The course.